# Aflibercept

## Eylea aflibercept 2mg/0.05mL

| TAH Drug Code      | [IEYL](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IEYL)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of neovascular (wet) age-related macular degeneration (AMD).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dosing             | Wet type (Neovascular) of age-related macular degeneration (wAMD): 2 mg every 4 weeks for the first 3 injections then every 8 weeks thereafter. Macular edema following central retinal vein occlusion (CRVO): 2 mg every 4 weeks via IVIA. Diabetic macular edema: 2 mg every 4 weeks for the first 5 injections, followed by 2 mg every 8 weeks. Macular edema induced visual impairment following branch retinal vein occlusion (BRVO): 2 mg every 4 weeks for the first 6 injections, followed by 2 mg every 8 weeks. Choroidal neovascularization(CNV) following pathological myopia: 2 mg single dose via IVIA. May repeat 1 to 3 times a year with the 1 month- interval according to the doctor's judgment on vision and/or anatomy.                                                       |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | 1.Ocular or periocular infection 2.Active intraocular inflammation 3.Hypersensitivity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | >10%: Ocular: Conjunctival hemorrhage (12% to 25%), eye pain (9% to 13%) 1% to 10%: Local: Injection site pain (3%), injection site hemorrhage (1%) Ocular: Intraocular pressure increased (5% to 8%), cataract (7%), vitreous detachment (6%), vitreous floaters (5% to 6%), conjunctival hyperemia (4% to 5%), corneal erosion (4% to 5%), foreign body sensation (3%), lacrimation increased (3%), retinal pigment epithelium detachment (3%), blurred vision (1% to 2%), retinal pigment epithelium tear (2%), eyelid edema (1%), corneal edema (1%) Miscellaneous: Aflibercept antibodies (1% to 3%) <1% (Limited to important or life-threatening): Endophthalmitis, hypersensitivity, intraocular inflammation, retinal detachment, retinal tear, thromboembolic events, traumatic cataract |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

